Detailed description page of B3Pdb
This page provides detail information of Selected ID b3pdb_1218 |
| Primary information | |
|---|---|
| B3PDB ID | b3pdb_1218 |
| Peptide Name | dNP2 |
| PEPTIDE SEQUENCE (1-letter) | KIKKVKKKGRKGSKIKKVKKKGRK |
| PEPTIDE SEQUENCE (3-letter) | NA |
| N-terminal modification | NA |
| C-terminal modification | NA |
| Chemical modification | NA |
| Peptide Length | 24 |
| Conformation | NA |
| Peptide Nature | Cationic |
| Source/Origin of peptide | Chemically synthesized |
| SMILES | NA |
| Cell Line | Jurkat cells |
| In vitro CONCENTRATION | 2 μM |
| In vitro METHOD | Confocal microscopy |
| In vitro RESULT | dNP2 enables the delivery of LRR domain of NLRX1 into T cells |
| ANIMAL MODEL | C57BL/6J Mice |
| In vivo CONCENTRATION | NA |
| In vivo MODE OF DELIVERY | Intraperitoneal |
| In vivo METHOD | Confocal microscopy |
| In vivo RESULT | dNP2 enables the delivery of LRR domain of NLRX1 into T cells |
| ACTION | It directly inhibits the functions of effector T cells and ameliorates disease severity of EAE with |
| TRANSPORT TYPE | NA |
| SUBCELLULAR LOCALISATION | NA |
| COMBINATION | Combined with LRR |
| PHYSICAL CONDITION | Encephalomyelitis |
| RESPONSE | NA |
| RESULT | NA |
| LABEL | NA |
| PMID | 32194859 |